Free Trial
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Rigel Pharmaceuticals logo
$18.92 +0.27 (+1.42%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Key Stats

Today's Range
$18.65
$19.18
50-Day Range
$18.26
$21.85
52-Week Range
$7.48
$29.82
Volume
97,440 shs
Average Volume
210,148 shs
Market Capitalization
$338.01 million
P/E Ratio
9.14
Dividend Yield
N/A
Price Target
$36.40
Consensus Rating
Hold

Company Overview

Rigel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

RIGL MarketRank™: 

Rigel Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 1354th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Rigel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rigel Pharmaceuticals is 9.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.54.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rigel Pharmaceuticals is 9.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

  • Price to Book Value per Share Ratio

    Rigel Pharmaceuticals has a P/B Ratio of 99.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Rigel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.09% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rigel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rigel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.09% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rigel Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.48% of the stock of Rigel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rigel Pharmaceuticals' insider trading history.
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Stock News Headlines

RIGL Rigel Pharmaceuticals, Inc. - Seeking Alpha
Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
See More Headlines

RIGL Stock Analysis - Frequently Asked Questions

Rigel Pharmaceuticals' stock was trading at $16.82 at the beginning of the year. Since then, RIGL shares have increased by 12.5% and is now trading at $18.9150.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.14 by $0.49. The biotechnology company earned $53.33 million during the quarter, compared to analyst estimates of $43.87 million. Rigel Pharmaceuticals had a net margin of 18.31% and a negative trailing twelve-month return on equity of 655.26%.
Read the conference call transcript
.

Rigel Pharmaceuticals's stock reverse split before market open on Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
5/06/2025
Today
7/03/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RIGL
Employees
160
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$36.40
High Stock Price Target
$57.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+92.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
9.14
Forward P/E Ratio
85.98
P/E Growth
N/A
Net Income
$17.49 million
Pretax Margin
18.77%

Debt

Sales & Book Value

Annual Sales
$179.28 million
Cash Flow
$1.09 per share
Price / Cash Flow
17.34
Book Value
$0.19 per share
Price / Book
99.55

Miscellaneous

Free Float
16,178,000
Market Cap
$338.01 million
Optionable
Optionable
Beta
1.26

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:RIGL) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners